A LONG-TERM SURVEY OF MORPHINE IN CANCER PAIN PATIENTS

被引：109

作者：

SCHUG, SA

ZECH, D

GROND, S

JUNG, H

MEUSER, T

STOBBE, B

机构：

[1] Department of Pharmacology and Clinical Pharmacology, School of Medicine, University of Auckland, Auckland

[2] Department of Anesthesiology, University of Cologne, Cologne

来源：

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT | 1992年 / 7卷 / 05期

关键词：

CANCER PAIN; WHO GUIDELINES; MORPHINE; COANALGESICS; PHYSICAL DEPENDENCE; TOLERANCE; ADDICTION; SIDE EFFECTS;

D O I：

10.1016/0885-3924(92)90059-Q

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

We surveyed 550 cancer patients who experienced pain and were treated with morphine for a total of 22,525 treatment days. Sufficient pain relief was achieved during more than 80% of this time using an average oral morphine dose of 82.4 mg-significantly lower than other studies. The use of this low dose, which was possible due to the concomitant administration of nonopioids and specific coanalgesics in most patients, resulted in a low incidence of side effects. Constipation and nausea/vomiting were the most common of these side effects. Physical dependence posed no practical problem in discontinuation Of morphine treatment. Long-term opioid intake and development of tolerance did not appear to be linked; an increase in morphine dosage was most often explained by progression of the terminal disease. Addiction was a negligible problem, with only one observed case.

引用

页码：259 / 266

页数：8

共 42 条

[1]

Saunders, The management of terminal malignant disease, (1984)

[2]

Twycross, Lack, Therapeutics in terminal cancer, (1984)

[3]

World Health Organization (WHO), Cancer pain relief, (1986)

[4]

International Narcotics Control Board, Demand and supply of opiates for medical and scientific needs, (1989)

[5]

Schug, Zech, Doerr, Cancer pain management according to WHO analgesic guidelines, Journal of Pain and Symptom Management, 5, pp. 27-32, (1990)

[6]

Cundiff, McCarthy, Savarese, Et al., Evaluation of a cancer pain model for the testing of long acting analgesics, Cancer, 63, pp. 2355-2359, (1989)

[7]

Goughnour, Arkinstall, Stewart, Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients, Cancer, 63, pp. 2294-2297, (1989)

[8]

Neumann, Henriksen, Grosman, Christensen, Plasma morphine concentrations during chronic oral administration in patients with cancer pain, Pain, 13, pp. 247-252, (1982)

[9]

Gourlay, Cherry, Cousins, A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 25, pp. 297-312, (1986)

[10]

Kalso, Vainio, Morphine and oxycodone hydrochloride in the management of cancer pain, Clin Pharmacol Ther, 47, pp. 639-646, (1990)

← 1 2 3 4 5 →